ClinicalTrials.gg
CompletedNCT00770432Updated Oct 2, 2018Results posted

Study Comparing PEG 3350 Laxative to Placebo in the Treatment of Occasional Constipation (Study CL2007-12)(P08216)

A Phase 4 interventional study of Polyethylene glycol 3350 and Placebo, maltodextrin 500 powder for solution in Constipation, sponsored by Bayer. Completed. Open to participants aged 17 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-10-02.

Sponsored by Bayer · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
203
Allocation
Randomized
Ages
17 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies testing polyethylene glycol 3350 in Constipation — 3 open to participants now, 4 under way, none of them phase 3. polyethylene glycol 3350 · Constipation.

Enrollment
7th of 27
203 · median 100
Started
2007
with 2 others
Phase 4
16 of 27
2 open now
Registered
11th of 27
by date
Lead sponsor
3 of 27
Bayer

Among the 27 studies testing polyethylene glycol 3350 in Constipation, this one is the 7th largest by enrollment, is one of 3 that started in 2007, is one of 16 in phase 4, and was the 11th registered.

Constipation

1,047 studies on the registry are indexed under Constipation; 161 are open to participants now.

Browse Constipation studies →

Open to participants now

3 of the 27 studies testing polyethylene glycol 3350 in Constipation are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About polyethylene glycol 3350

polyethylene glycol 3350: first FDA approval 1984 (GOLYTELY). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 99 Constipation studies recruiting now, 32 (32%) set no upper age limit and 52 (53%) stop at 75 or younger; 17 take children under 18; 28 take healthy volunteers.

This study: 17 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing polyethylene glycol 3350 in Constipation, or all of them as a file.
02

Study summary

Randomized, placebo-controlled, double blind study. 203 subjects entered the study to compare the effect on occasional constipation of polyethylene glycol 3350 to placebo. Subjects took one of study treatments up to 7 days.

03

Conditions studied

  • Constipation

Browse trials for

Keywords

  • Human Experimentation
04

Who can participate

Ages eligible
17 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects (or parents/guardians of minors) must demonstrate their willingness to participate (or to have their children/wards participate) in the study and comply with its procedures by signing a written . Minor subjects must provide written assent.
  • Subjects must be 17 years of age or older.
  • Subjects must present with a current diagnosis of untreated constipation for 7 days or less based on having signs/symptoms of straining and hard or lumpy stools OR the inability to have a BM within 48 hours prior to randomization into the trial.
  • Subjects must be OTC laxative users for the treatment of occasional constipation (defined as using a nonprescription laxative to treat at least 3 episodes of constipation within the last 12 months prior to randomization).
  • Subjects must be willing to use study drug for up to 7 days as directed, and must agree to record bowel movement (frequency, consistency, etc.) accurately and consistently in a daily diary, and make two clinic visits.
  • Subjects must be otherwise in good health, as determined by physical exam and medical history.
  • Subjects must agree not to use any other products to treat their constipation during the course of the study.
  • Subjects must agree not to use any medication known to cause constipation during the course of the study.
  • Subjects must agree to maintain a similar diet from the week prior to randomization through end of study.
  • Female subjects must be either surgically sterile, 2 years , or they attest that they are using an acceptable method of (including hormonal birth control, IUD, double barrier methods, or vasectomized partner). In females of , the urine pregnancy test (HCG) must be negative at Baseline.
  • Subjects must be able to read the diaries in English.

Exclusion criteria

Exclusion Criteria:

  • Subjects currently under a doctor's care and treatment for constipation.
  • Subjects having current constipation episode for more than one week prior to randomization.
  • Subjects that have a history of chronic constipation due to any underlying cause (inflammatory bowel disease, etc.).
  • Subjects have a history of more than 3 months of constipation in the past year.
  • Subjects have severe abdominal pain as the predominant constipation symptom.
  • Subjects who have previously used a polyethylene glycol laxative.
  • Subjects who have celiac disease or known gluten sensitivity.
  • Subjects who have a history of colorectal cancer, anal abscess, anal fistula, anal fissure, anal stenosis, gastric retention or obstruction, bowel resection, rectocele, or colostomy.
  • Subjects with known renal or hepatic insufficiency.
  • Subjects with gastrointestinal bleeding or acute infection.
  • Subjects with a history of alcohol or drug abuse.
  • Subjects with a history of psychiatric disorders.
  • Subjects with a history of significant ongoing medical problems, including kidney disease, or who are scheduled for surgical procedures.
  • Subjects currently taking or taken within 7 days of randomization a concomitant medication that causes constipation including for example opiates, antidepressants, SSRI's, antimotility agents, and anticholinergics, etc.
  • Subjects who plan to use laxatives during the treatment period other than the study medication.
  • Subjects who, in the opinion of the investigator, should not be included in the study for any reason, including inability to follow study procedures.
  • Subjects who have participated in an clinical surgical, drug or device study within the past 30 days.
  • Subjects who are pregnant or lactating.
  • Subjects who are allergic to polyethylene glycol or maltodextrin.
  • Subjects who are employed or have immediate family members employed by a company that manufactures laxative products.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
203 participants (actual)

Study arms

  • Active comparator
    Polyethylene glycol 3350 powder for solution

    MiraLAX® (polyethylene glycol 3350 powder for solution)

    Drug: Polyethylene glycol 3350

  • Placebo comparator
    Placebo

    MALTRIN 500® M500 (maltodextrin 500)

    Other: Placebo, maltodextrin 500 powder for solution

Interventions

  • Polyethylene glycol 3350 powder for solution. Single dose (17 grams in 4 to 8 ounces of beverage) for 7 days.

    Also known as: MiraLAX®

  • OtherPlacebo, maltodextrin 500 powder for solution

    Maltodextrin 500 powder for solution, One single dose (one capful) in any 4 - 8 ounces beverage for 7 days.

    Also known as: MALTRIN® 500 powder for solution

06

What researchers measure

Primary outcomes

  1. Number of Participants With a Complete Resolution at the Final Visit

    A resolution was recorded if the participant has no occurrence of two or more consecutive unsuccessful bowel movements for the rest of the study following the first successful bowel movement.

    Time frame: 24 hours to 3 days after last dose of seven day treatment period.

07

Results

Posted Aug 12, 2009

Participant flow

Participant flow — Overall Study
MilestonePolyethylene Glycol 3350 Powder for SolutionPlacebo
Started102101
Completed9894
Not completed47
Withdrew: Other46
Withdrew: Non-compliance01

Outcome measures

PrimaryNumber of Participants With a Complete Resolution at the Final Visit

A resolution was recorded if the participant has no occurrence of two or more consecutive unsuccessful bowel movements for the rest of the study following the first successful bowel movement.

Time frame:
24 hours to 3 days after last dose of seven day treatment period.
Reported as:
Number · Participants
Number of Participants With a Complete Resolution at the Final Visit
ParticipantsPolyethylene Glycol 3350 Powder for SolutionPlacebo
Number of Participants With a Complete Resolution at the Final Visit3623
Statistical analysis
  • Polyethylene Glycol 3350 Powder for Solution vs Placebo · Cochran-Mantel-Haenszel · p = 0.0595The Cochran-Mantel-Haenszel adjusted for study site (the smallest study sites were pooled according to a pre-specified rule).

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Polyethylene Glycol 3350 Powder for Solution—0/102 (0%)11/102 (10.8%)
Placebo—0/101 (0%)11/101 (10.9%)
Most frequent other events
Most frequent other events
EventPolyethylene Glycol 3350 Powder for SolutionPlacebo
HeadacheNervous system disorders11/10211/101

Baseline characteristics

Age, Continuous
Age, Continuous(years)Polyethylene Glycol 3350 Powder for SolutionPlaceboTotal
Mean45.8 ± 12.5245.0 ± 14.1545.4 ± 13.33
Sex: Female, Male
Sex: Female, Male(Participants)Polyethylene Glycol 3350 Powder for SolutionPlaceboTotal
Female7768145
Male253358
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • McGraw T. Polyethylene glycol 3350 in occasional constipation: A one-week, randomized, placebo-controlled, double-blind trial. World J Gastrointest Pharmacol Ther. 2016 May 6;7(2):274-82. doi: 10.4292/wjgpt.v7.i2.274. PubMed 27158544 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2007, a primary completion of Jan 2008 and a completion of Jan 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2009, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 9, 2008
First posted
Oct 10, 2008
Start
Nov 2007
Primary completionActual
Jan 2008
CompletionActual
Jan 2008
Results first posted
Aug 12, 2009
Last update
Oct 2, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 2, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00770432
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Oct 10, 2008
Start date
Nov 2007
Primary completion
Jan 2008
Completion
Jan 2008
Results posted
Aug 12, 2009
Last update
Oct 2, 2018

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Polyethylene glycol 3350

Start the discussion